Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Organigram Global Inc. (OGI.TO)
CAD1.21
-0.04 (-3.20%)
CA TSX Healthcare Drug Manufacturers - Specialty & Generic
Address
145 King Street West M5H 1J8
Toronto, ON, CA
Toronto, ON, CA
CEO
James Hideo Yamanaka
Website
organigram.ca
IPO
2012-01-05
ISIN CA68617J1003
Also trades on
NASDAQ Global Select · OGI (USD)
Toronto Stock Exchange · OGI.TO (CAD)
Description
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD1.21
-0.04 (-3.20%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
181.5K
Beta
1.85
Float Shares
90.51M
Free Float %
66.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -18.95% | -22.22% | -11.49% | -28.70% | -33.33% | -10.47% | -38.89% | -86.99% | -67.92% | +30.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
1.21
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.22
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+62.2% ★ Q1'26: -8.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+60.4% ★ Q1'26: -102.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-10.0% Q1'26: -10.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-14.9% Q1'26: -55.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-14.1% Q1'26: -40.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+34.0% Q1'26: -1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.43× Q1'26: -0.06× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 3 Rev. Ana. 1 EPS Ana. |
Sep 2027 4 Rev. Ana. 2 EPS Ana. |
Sep 2028 1 Rev. Ana. 1 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
Sep 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
986.7K
est: 800.0K (+23.3%)
|
6.13M
est: 6.33M (-3.2%)
|
5.39M
est: 7.58M (-28.9%)
|
12.43M
est: 14.16M (-12.2%)
|
80.41M
est: 85.85M (-6.3%)
|
86.80M
est: 87.50M (-0.8%)
|
79.16M
est: 78.33M (+1.1%)
|
145.81M
est: 142.54M (+2.3%)
|
149.21M
est: 155.64M (-4.1%)
|
159.84M
est: 160.47M (-0.4%)
|
259.18M
est: 252.11M (+2.8%)
|
344.33M
333.59M – 352.35M
+36.6% YoY
|
447.65M
439.00M – 456.12M
+30.0% YoY
|
474.90M
463.27M – 484.79M
+6.1% YoY
|
506.00M
493.61M – 516.53M
+6.5% YoY
|
539.70M
526.48M – 550.93M
+6.7% YoY
|
| EBITDA |
-747.0K
est: -344.3K (-117.0%)
|
2.07M
est: -2.72M (+175.9%)
|
-8.99M
est: -3.26M (-175.7%)
|
39.94M
est: -6.09M (+755.5%)
|
12.70M
est: -36.95M (+134.4%)
|
-121.48M
est: -37.66M (-222.6%)
|
-95.59M
est: -33.71M (-183.6%)
|
10.97M
est: -61.34M (+117.9%)
|
-207.62M
est: -66.98M (-210.0%)
|
-23.59M
est: -69.06M (+65.8%)
|
-20.55M
est: -108.49M (+81.1%)
|
-148.18M
-151.63M – -143.56M
-36.6% YoY
|
-192.64M
-196.29M – -188.92M
-30.0% YoY
|
-204.37M
-208.62M – -199.36M
-6.1% YoY
|
-217.75M
-222.28M – -212.42M
-6.5% YoY
|
-232.25M
-237.09M – -226.57M
-6.7% YoY
|
| EBIT |
-1.16M
est: -394.8K (-194.1%)
|
1.28M
est: -3.12M (+141.1%)
|
-10.55M
est: -3.74M (-182.0%)
|
37.87M
est: -6.99M (+641.9%)
|
3.79M
est: -42.37M (+109.0%)
|
-139.43M
est: -43.18M (-222.9%)
|
-126.63M
est: -38.66M (-227.6%)
|
-12.58M
est: -70.34M (+82.1%)
|
-231.79M
est: -76.81M (-201.8%)
|
-35.67M
est: -79.19M (+55.0%)
|
-38.53M
est: -124.41M (+69.0%)
|
-169.92M
-173.88M – -164.62M
-36.6% YoY
|
-220.91M
-225.09M – -216.64M
-30.0% YoY
|
-234.36M
-239.24M – -228.62M
-6.1% YoY
|
-249.70M
-254.90M – -243.59M
-6.5% YoY
|
-266.34M
-271.88M – -259.81M
-6.7% YoY
|
| Net Income |
-1.28M
est: -20.43M (+93.7%)
|
846.7K
est: -3.83M (+122.1%)
|
-10.89M
est: -43.12M (+74.7%)
|
20.51M
est: -19.15M (+207.1%)
|
-9.54M
est: 34.73M (-127.5%)
|
-136.16M
est: -273.20M (+50.2%)
|
-130.70M
est: -216.76M (+39.7%)
|
-14.28M
est: -30.64M (+53.4%)
|
-229.48M
est: -348.47M (+34.1%)
|
-45.44M
est: -53.81M (+15.6%)
|
-24.76M
est: 10.52M (-335.3%)
|
16.56M
16.07M – 17.05M
+57.3% YoY
|
6.37M
6.18M – 6.56M
-61.5% YoY
|
21.70M
21.01M – 22.29M
+240.8% YoY
|
28.09M
27.19M – 28.85M
+29.4% YoY
|
33.20M
32.14M – 34.09M
+18.2% YoY
|
| SGA |
2.49M
est: 357.7K (+594.7%)
|
4.07M
est: 2.83M (+43.7%)
|
7.39M
est: 3.39M (+118.2%)
|
15.22M
est: 6.33M (+140.3%)
|
41.30M
est: 38.39M (+7.6%)
|
46.47M
est: 39.13M (+18.8%)
|
46.52M
est: 35.03M (+32.8%)
|
59.21M
est: 63.73M (-7.1%)
|
71.68M
est: 69.59M (+3.0%)
|
68.14M
est: 71.75M (-5.0%)
|
86.88M
est: 112.73M (-22.9%)
|
153.96M
149.16M – 157.55M
+36.6% YoY
|
200.16M
196.29M – 203.95M
+30.0% YoY
|
212.35M
207.15M – 216.77M
+6.1% YoY
|
226.25M
220.71M – 230.96M
+6.5% YoY
|
241.32M
235.41M – 246.35M
+6.7% YoY
|
| EPS |
-0.10
est: -0.16 (+39.1%)
|
0.06
est: -0.03 (+286.7%)
|
-0.45
est: -0.34 (-33.2%)
|
0.68
est: -0.15 (+553.3%)
|
-0.27
est: 0.27 (-199.3%)
|
-3.15
est: -2.14 (-47.2%)
|
-2.04
est: -1.70 (-20.2%)
|
-0.18
est: -0.24 (+25.0%)
|
-2.82
est: -2.70 (-4.3%)
|
-0.48
est: -0.42 (-13.6%)
|
-0.19
est: 0.08 (-330.0%)
|
0.13
0.13 – 0.13
+57.3% YoY
|
0.05
0.05 – 0.05
-61.5% YoY
|
0.17
0.16 – 0.17
+240.0% YoY
|
0.22
0.21 – 0.23
+29.4% YoY
|
0.26
0.25 – 0.27
+18.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
114.65M
OE per share TTM
0.85
Owner's Yield
47.21%
Maintenance CapEx ratio
128.05%
Maint CapEx / Avg PPE
133.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 3 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/TSX SmallCap Index ETF XCS.TO | 0.05% | 77.1K | 0.60% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 46.0K | 0.22% |
| 3 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-33.9K
Shares Outstanding
136.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James H. Yamanaka | Chief Executive Officer & Director | 761.3K | male |
| Timothy Emberg | President of Organigram Canada | 464.9K | male |
| Greg Guyatt | Chief Financial Officer | 464.8K | male |
| Helen Martin | Chief Legal Officer & Corporate Secretary | 462.7K | female |
| Paolo De Luca | Chief Strategy Officer | 440.8K | male |
| Peter L. Amirault | Executive Chairman | 95.0K | male |
| Valerie Rother | Chief People Officer | — | female |
| Katrina May McFadden | Chief People Officer | — | female |
| Max Schwartz | Director of Investor Relations | — | — |
| Megan Amber McCrae | Senior Vice President of Corporate Strategy & International Growth | — | female |
| Nathalie Batten | Senior Vice President of Operations | — | female |
| Bradley Gunter | Senior Vice President of Sales | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OGI.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
